FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings
Date
The Federal Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration’s (FDA) publication of “Approved...